IFN-alpha 2 Antibody (967314) [Unconjugated]

IFN-a2/IFNA2 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Mouse Anti-Human IFN-a2/IFNA2 Monoclonal Antibody (Catalog # MAB9345) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

• Reactivity: Hu
• Applications: ICC/IF
• Clone: 967314
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IFN-alpha 2 Antibody (967314) [Unconjugated] Summary

• Immunogen: Human embryonic kidney cell line HEK-293-derived transfected with human IFN-alpha 2/IFNA2
  Met1-Glu188
  Accession # P01563
• Specificity: Detects human IFN-alpha 2/IFNA2 in ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) IFNE, rhIFNB, rhIFNG, or recombinant cotton rat IFNA is observed. In sandwich ELISAs, less than 8% cross-reactivity with rhIFNA-7, rhIFNA-8, and rhIFNA-10 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 8-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IFN-alpha 2 Antibody (967314) [Unconjugated]

• alpha-2a interferon
• Ifa2
• IFNA
• IFNA2
• IFNA2a
• IFNA2b
• IFNA2c
• IFNAA
• IFNalpha 2
• IFN-alpha 2
• IFN-alpha-2
• IFN-alphaA
• INFA2
• interferon alpha 2b
• interferon alpha A
• interferon alpha-2
• Interferon alpha-A
• interferon, alpha 2
• LeIF A
• MGC125764
• MGC125765

Background

Interferon-alpha 2 (IFNA2), also known as leukocyte interferon, is a type I interferon  produced by macrophages,  CD8 resting T cells, tonsillar NK cells, germinal center B cells, as well as epithelial cells, tumor cells and melanocytes. IFN alpha has at least nine different isoforms.

IFNA2 is a ligand for a cell surface receptor with two subunits, IFN-alpha R2 (ligand binding) and IFN-alpha R1 (ligand binding and signal transduction). IFNA2 has both antiviral and immunomodulatory activities on target cells.  Intranasal administration has been shown to reduce viral load in subjects with the common cold. While IFNA2 is a prognostic factor for hepatocellular carcinoma, Interferon alpha 2b, has been used to treat melanoma, renal cell carcinoma, chronic myelogenous leukemia and hepatitis C.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P01563()